# OnCo record ignace-vergote (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/ignace-vergote/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "ignace-vergote" ;
  schema:name "Ignace Vergote"@en ;
  schema:description "Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer."@en ;
  schema:url <https://onco.cc/people/ignace-vergote/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Vergote%20I%5BAuthor%5D%20ovarian%20OR%20cervical> ;
  onco:tag "ovarian", "cervical", "adc", "cooperative-group" ;
  schema:jobTitle "Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/tissue-factor/> ;
  onco:drugs <https://onco.cc/drugs/tisotumab-vedotin/> ;
  onco:institutions <https://onco.cc/institutions/uz-leuven/> ;
  onco:trials <https://onco.cc/trials/innovatv-301/> ;
  schema:affiliation <https://onco.cc/institutions/uz-leuven/> .